Fundraising Fox

Klotho

Founded 2016 · 2 employees on LinkedIn · 1 known investors

Klotho Therapeutics is a biotech company developing protein-based therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney disease, diabetes, and cancer. The company focuses on longevity treatment and aims to enter human trials within two years targeting kidney disease.

BiotechHealthtechLongevity

Investors · 1

Thynk Capitalvia Jim Plante · inferred

In the news

Klotho Neurosciences Raises $7.75 Million in Private Placement - TipRanks.comtipranks.com · Mar 2026Klotho Neurosciences Raises $11 Million In Funding | citybizcitybiz.co · Jun 2025Klotho Neurosciences Raises $11M, Achieves Zero Debt and NASDAQ Compliance | KLTO Stock Newsstocktitan.net · Jun 2025Klotho Neurosciences raises $11 million, eliminates all debt By Investing.cominvesting.com · Jun 2025KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT - BioSpacebiospace.com · Jun 2025Klotho Therapeutics Raises $10 M in Funding Round - San Diego Business Journalsdbj.com · Nov 2017

Frequently asked questions

What does Klotho do?
Klotho Therapeutics is a biotech company developing protein-based therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney disease, diabetes, and cancer. The company focuses on longevity treatment and aims to enter human trials within two years targeting kidney disease.
Who are Klotho's investors?
Klotho's investors include Thynk Capital.